Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Nov;56(11):3617-3625.
doi: 10.1007/s11255-024-04099-1. Epub 2024 Jun 12.

Clinical value of adding Dapagliflozin in patients with nephrotic syndrome

Affiliations
Randomized Controlled Trial

Clinical value of adding Dapagliflozin in patients with nephrotic syndrome

Magdy ElSharkawy et al. Int Urol Nephrol. 2024 Nov.

Abstract

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors in nephrotic patients on immunosuppression are underexplored. We evaluated dapagliflozin's impact in non-diabetic primary nephrotic syndrome.

Methods: Randomized controlled clinical trial was conducted on 60 non-diabetic primary nephrotic syndrome patients, equally assigned to dapagliflozin and control groups. All patients received the standard of care medication and the Dapagliflozin group received 10 mg dapagliflozin in addition. Demographic data, nephrotic syndrome etiology, proteinuria levels, eGFR, and immunosuppression doses, were well-matched. After 6 months of follow up primary outcomes included changes in and eGFR.

Results: Both groups exhibited significant reductions in proteinuria after 6 months, with the dapagliflozin group achieving a mean UPCR reduction of - 94.7%, and the control group - 86.7% (p < 0.001). However, the comparative change in proteinuria between both groups did not reach statistical significance (p = 0.158). Dapagliflozin initially led to a transient eGFR decline. Dapagliflozin also resulted in a significant mean body weight reduction (p < 0.001) and notable improvements in triglyceride levels compared to the control group (p = 0.045).

Conclusion: In primary nephrotic syndrome patients, adjunct dapagliflozin may enhance the standard of care. While notable, the reduction in proteinuria was comparable to that of the control group by the study's end. Furthermore, after 6 months, eGFR remained stable in both groups. However, significant weight loss and serum triglyceride reduction were particularly pronounced in the dapagliflozin group. Further long-term investigations are necessary to address potential immunosuppression-related confounding effects in patients with primary glomerular disease.

Keywords: Dapagliflozin; Nephrotic syndrome; Proteinuria; SGLT2i; eGFR.

PubMed Disclaimer

Similar articles

References

    1. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TA et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4):S1–S276. https://doi.org/10.1016/j.kint.2021.05.021 - DOI
    1. Hull RP, Goldsmith DJA (2008) Nephrotic syndrome in adults. BMJ 336(7654):1185–1189. https://doi.org/10.1136/bmj.39576.709711.80 - DOI - PubMed - PMC
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446. https://doi.org/10.1056/nejmoa2024816 - DOI - PubMed
    1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. https://doi.org/10.1056/nejmoa1811744 - DOI - PubMed
    1. Herrington WG, Staplin N, Wanner C, Green JB, Judge P, Mayne KJ (2023) Empagliflozin in patients with Chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233 - DOI - PubMed

Publication types

LinkOut - more resources